X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
open-label (2246) 2246
index medicus (1996) 1996
humans (1876) 1876
double-blind (997) 997
male (751) 751
female (726) 726
pharmacology & pharmacy (724) 724
treatment outcome (599) 599
middle aged (504) 504
care and treatment (497) 497
efficacy (496) 496
adult (487) 487
oncology (474) 474
safety (457) 457
drug therapy (433) 433
aged (409) 409
medicine & public health (407) 407
clinical neurology (394) 394
clinical trials (387) 387
placebo-controlled trial (333) 333
analysis (315) 315
research (293) 293
psychiatry (282) 282
chemotherapy (275) 275
patients (270) 270
cancer (246) 246
neurosciences (222) 222
adolescent (220) 220
health aspects (219) 219
internal medicine (219) 219
animals (217) 217
therapy (209) 209
quality-of-life (205) 205
review (205) 205
randomized controlled trials as topic (202) 202
multicenter (200) 200
pharmacotherapy (197) 197
dosage and administration (192) 192
endocrinology & metabolism (189) 189
open-label extension (187) 187
diabetes mellitus, type 2 - drug therapy (183) 183
medical research (183) 183
studies (181) 181
diabetes (180) 180
quality of life (180) 180
child (178) 178
type 2 diabetes (177) 177
double-blind method (171) 171
clinical trials as topic (170) 170
mutation (164) 164
randomized controlled-trial (164) 164
usage (161) 161
neurology (156) 156
trial (156) 156
risk factors (155) 155
1st-line treatment (154) 154
pharmacology/toxicology (154) 154
aged, 80 and over (152) 152
metastasis (152) 152
children (151) 151
medicine, general & internal (151) 151
glycemic control (149) 149
drug therapy, combination (147) 147
open-label trial (144) 144
pharmacokinetics (139) 139
young adult (138) 138
phase-iii (136) 136
dose-response relationship, drug (132) 132
medicine, experimental (131) 131
tolerability (131) 131
time factors (129) 129
medicine, research & experimental (128) 128
hypoglycemic agents - therapeutic use (127) 127
management (127) 127
drug administration schedule (126) 126
rheumatology (125) 125
antipsychotic agents - therapeutic use (121) 121
pharmacology (120) 120
insulin (118) 118
pediatrics (118) 118
complications and side effects (117) 117
severity of illness index (114) 114
dermatology (109) 109
patient outcomes (108) 108
cancer therapies (107) 107
antineoplastic agents - therapeutic use (106) 106
development and progression (104) 104
hematology (104) 104
retrospective studies (104) 104
toxicology (104) 104
tumors (104) 104
drugs (102) 102
psoriasis (102) 102
schizophrenia (101) 101
lung cancer (100) 100
abridged index medicus (99) 99
immunotherapy (99) 99
survival (99) 99
drug dosages (98) 98
hypoglycemic agents - administration & dosage (98) 98
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2680) 2680
German (7) 7
French (4) 4
Japanese (2) 2
Russian (2) 2
Spanish (2) 2
Georgian (1) 1
Hungarian (1) 1
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Schizophrenia Research, ISSN 0920-9964, 2017, Volume 192, pp. 205 - 210
Abstract Objective To evaluate long-term safety and effectiveness of continued treatment with aripiprazole once-monthly 400 mg (AOM 400) in patients with... 
Psychiatry | Schizophrenia | Aripiprazole once-monthly | Maintenance treatment | Quality of life | PSYCHIATRY WFSBP GUIDELINES | MULTICENTER | PSYCHIATRY | OPEN-LABEL | BIOLOGICAL TREATMENT | ANTIPSYCHOTICS | DOUBLE-BLIND | LIFE SCALE | PART 2 | WORLD FEDERATION | Aripiprazole | Analysis
Journal Article
EPILEPSIA, ISSN 0013-9580, 01/2013, Volume 54, Issue 1, pp. 126 - 134
Purpose: To evaluate safety, tolerability, and seizure outcome data during long-term treatment with once-daily adjunctive perampanel (up to 12 mg/day) in... 
EFFICACY | Partial epilepsy | Perampanel | LONG-TERM SAFETY | a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | ADULTS | Long-term | Open-label | Safety | EPILEPSY | OPEN-LABEL EXTENSION | CLINICAL NEUROLOGY
Journal Article
Journal of Women's Health, ISSN 1540-9996, 02/2019, Volume 28, Issue 2, pp. 17 - 177
Background: Dienogest provided significantly greater reduction in endometriosis-associated pelvic pain (EAPP) than placebo in a 24-week, randomized,... 
Original Articles | endometriosis | Chinese women | dienogest | open-label study | MULTICENTER | EFFICACY | SYMPTOMS | TERM | LEUPROLIDE ACETATE | OBSTETRICS & GYNECOLOGY | MEDICINE, GENERAL & INTERNAL | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | PAIN | WOMENS STUDIES
Journal Article
by Murai, Hiroyuki and Uzawa, Akiyuki and Suzuki, Hidekazu and Suzuki, Yasushi and Suzuki, Shuichiro and Imai, Tomihiro and Shiraishi, Hirokazu and Okumura, Meinoshin and O’Brien, Fanny and Wang, Yunxia and Wang, Jing-Jing and Fujita, Kenji P and Utsugisawa, Kimiaki and Mazia, Claudio Gabriel and Wilken, Miguel and Barroso, Fabio and Saba, Juliet and Rugiero, Marcelo and Bettini, Mariela and Chaves, Marcelo and Vidal, Nuria and Vidal, Gonzalo and Garcia, Rebekah and Garcia, Sonia and Garcia, Alejandra Dalila and De Bleecker, Jan and Van den Abeele, Guy and de Koning, Kathy and De Mey, Katrien and Mercelis, Rudy and Mahieu, Délphine and Wagemaekers, Linda and Van Damme, Philip and Depreitere, Annelies and Schotte, Caroline and Smetcoren, Charlotte and Stevens, Olivier and Van Daele, Sien and Vandenbussche, Nicolas and Vanhee, Annelies and Verjans, Sarah and Vynckier, Jan and D'Hondt, Ann and Tilkin, Petra and Alves de Siqueira Carvalho, Alzira and Dias Brockhausen, Igor and Feder, David and Ambrosio, Daniel and César, Pamela and Melo, Ana Paula and Martins Ribeiro, Renata and Rocha, Rosana and Bezerra Rosa, Bruno and Veiga, Thabata and da Silva, Luiz Augusto and Santos Engel, Murilo and Gonçalves Geraldo, Jordana and Ananias Morita, Maria da Penha and Nogueira Coelho, Erica and Paiva, Gabriel and Pozo, Marina and Prando, Natalia and Martineli Torres, Debora Dada and Butinhao, Cristiani Fernanda and Duran, Gustavo and Gomes da Silva, Tamires Cristina and Otavio Maia Gonçalves, Luiz and Pazetto, Lucas Eduardo and Fialho, Tomás Augusto Suriane and Renata Cubas Volpe, Luciana and Souza Duca, Luciana and Souza Bulle Oliveira, Acary and Amaral Andrade, Ana Carolina and Annes, Marcelo and Duarte Silva, Liene and Cavalcante Lino, Valeria and Pinto, Wladimir and Assis, Natália and Carrara, Fernanda and Miranda, Carolina and Souza, Iandra and Fernandes, Patricia and Siddiqi, Zaeem and Phan, Cecile and Narayan, Jeffrey and Blackmore, Derrick and Mallon, Ashley and Roderus, Rikki and Watt, Elizabeth and Junkerova, Jana and Kurkova, Barbora and Reguliova, Katarina and Zapletalova, Olga and Pitha, Jiri and Novakova, Iveta and Tyblova, Michaela and Jurajdova, Ivana and Wolfova, Marcela and Andersen, Henning and Harbo, Thomas and ... and Collaboration REGAIN Study Grp
Journal of the Neurological Sciences, ISSN 0022-510X, 12/2019, Volume 407, p. 116419
The terminal complement inhibitor eculizumab was shown to improve myasthenia gravis-related symptoms in the 26-week, phase 3, randomized, double-blind,... 
Eculizumab | Japanese patients | Myasthenia gravis | MG-ADL | Open-label extension study | MG-QoL15 | COMPLEMENT INHIBITOR ECULIZUMAB | HLA | NEUROSCIENCES | ONSET | CLINICAL NEUROLOGY
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2017, Volume 128, pp. 50 - 56
Abstract Background Riociguat was well tolerated and improved exercise and functional capacity in patients with pulmonary arterial hypertension (PAH) and... 
Pulmonary/Respiratory | Soluble guanylate cyclase stimulator | Riociguat | Pulmonary hypertension | Clinical study | TRIAL | CARDIAC & CARDIOVASCULAR SYSTEMS | RESPIRATORY SYSTEM | PREDICTORS | OPEN-LABEL | HEMOPTYSIS | OUTCOMES | INTERNATIONAL PROSPECTIVE REGISTRY | Enzyme Activators - pharmacology | Antihypertensive Agents - pharmacology | Soluble Guanylyl Cyclase - metabolism | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Male | Enzyme Activators - administration & dosage | Adult | Female | Hypertension, Pulmonary - drug therapy | Walk Test - statistics & numerical data | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Hypertension, Pulmonary - mortality | Pulmonary Embolism - complications | Pyrimidines - administration & dosage | Treatment Outcome | Pyrimidines - pharmacology | Pulmonary Embolism - mortality | Disease-Free Survival | Pyrazoles - administration & dosage | Enzyme Activators - adverse effects | Pyrimidines - adverse effects | Pulmonary Embolism - drug therapy | Aged | Exercise - physiology | Clinical trials | Respiratory agents | Cardiology | Endothelin | Hypertension | Edema | Physical training | Health | Cut-off | Pulmonary arteries | Medical services | Rhinopharyngitis | Fatal | Patients | Survival | Walking | Hemoptysis | Functional anatomy | Functional morphology | Safety | Thromboembolism
Journal Article
Psychopharmacology, ISSN 0033-3158, 1/2017, Volume 234, Issue 2, pp. 199 - 209
Journal Article
Modern Rheumatology, ISSN 1439-7595, 01/2018, Volume 28, Issue 1, pp. 20 - 29
Objectives: The objective of this study is to evaluate the efficacy and safety of long-term (64 weeks; 52-week extension of a 12-week study) baricitinib... 
Arthritis, rheumatoid | baricitinib | Janus kinase | inflammation | Japan | INADEQUATE RESPONSE | AMERICAN-COLLEGE | Arthritis | OPEN-LABEL | RHEUMATOLOGY | COMBINATION | rheumatoid | LONG-TERM EXTENSION | BACKGROUND METHOTREXATE | THERAPY | JANUS KINASE INHIBITOR | TOFACITINIB
Journal Article